Top Markets
Coin of the day
NeoImmuneTech, Inc. NeoImmuneTech, Inc.

NeoImmuneTech, Inc.

950220
Rank in Stocks #33498
As a clinical-stage biotechnology firm with a strong focus on T cells,... As a clinical-stage biotechnology firm with a strong focus on T cells, NeoImmuneTech, Inc. is dedicated to creating and marketing innovative immunotherapies. The company's lead product, NT-I7, is a long-acting human IL-7 currently in clinical development for its potential to treat a range of oncologic and infectious conditions. Founded in 2014, NeoImmuneTech is based in Rockville, Maryland.
Share Price
$1.12
Last synced: 2026-08-14
Market Cap
$7.52M
Change (1 day)
4.51%
Change (1 year)
-94.79%
Country
US
Trade NeoImmuneTech, Inc. (950220)

Category

Operating Margin for NeoImmuneTech, Inc. (950220)
Operating Margin as of 2026 TTM: 0.00%
According to NeoImmuneTech, Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for NeoImmuneTech, Inc. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
38.59% -
US
28.81% -
NL
0.00% -
CH
0.00% -
KR
31.23% -
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.